Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy

Area of Science:

• Oncology
• Surgical Oncology
• Gastrointestinal Cancer Research

Background:

• Gastrointestinal cancer treatment and patient prognosis have seen minimal advancement over decades.
• Current screening methods lack the ability to detect gastrointestinal cancer for early-stage surgical cure.
• Adjuvant chemotherapy administered post-surgical resection has historically yielded limited success.

Purpose of the Study:

• To investigate novel approaches for improving gastrointestinal cancer treatment efficacy.
• To explore the potential of altered chemotherapy administration routes and timing.
• To evaluate the impact of immediate postsurgical intraperitoneal chemotherapy on disease progression.

Main Methods:

• Analysis of common sites for surgical treatment failure, including resection site recurrence and peritoneal spread.
• Modification of chemotherapy administration route and timing.
• Administration of intraperitoneal chemotherapy immediately following surgical resection.
• Exploration of drug delivery pharmacology and physiology in the immediate postoperative period.
• Performance of toxicity studies within existing treatment protocols.

Main Results:

• Resection site recurrence and peritoneal spread are identified as primary causes of surgical treatment failure.
• Altering chemotherapy administration route and timing demonstrates potential for improved drug efficacy.
• Early studies indicate a significant change in malignancy natural history with immediate postsurgical intraperitoneal chemotherapy.

Conclusions:

• Immediate postsurgical intraperitoneal chemotherapy represents a promising strategy to improve gastrointestinal cancer treatment.
• Further investigation through randomized controlled trials is warranted to validate these findings.
• Optimizing drug delivery in the postoperative period is crucial for enhancing therapeutic outcomes in gastrointestinal cancer.